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re-Procedural
lood Glucose Levels
New Risk Marker for
ontrast-Induced Acute Kidney Injury
n Patients Without Diabetes With
cute Myocardial Infarction*
artin A. Alpert, MD, Carl Carlino, MD
olumbia, Missouri
ontrast-induced acute kidney injury (AKI) is a common
omplication of procedures requiring the use of iodinated
adiographic contrast media (1–5). It is the third most
ommon cause of acute renal failure in hospitalized patients
nd is associated with higher short- and long-term morbid-
ty and mortality rates than are observed in patients without
ontrast-induced AKI (1–13).
The term “contrast-induced AKI” is favored by many
xperts over the more familiar “contrast-induced nephrop-
thy” (CIN) because it acknowledges that deterioration of
enal function after procedures that require the use of
odinated contrast media may be multifactorial (1). CIN is
n fact a form of contrast-induced AKI but is not the only
echanism for its occurrence (1–5).
See page 1433
Broadly speaking, contrast-induced AKI is defined as an
ncrease in the serum creatinine level beginning within the
rst 24 h after contrast exposure and peaking in most
atients up to 5 days after exposure (1–5). Most definitions
ave required a 0.5 to 1.0 mg/dl increase in the serum
reatinine level and/or a rise in the serum creatinine level to
5% to 50% above baseline (1–5). The most commonly used
efinition is an increase in the serum creatinine level 0.5
g/dl or a rise in the serum creatinine level of 25% or more
rom baseline when assessed 48 hours after contrast expo-
ure (1–5). Most recently, the Acute Kidney Injury Network
as defined contrast-induced AKI as a rise in the serum
reatinine level 0.3 mg/dl or an increase in the serum
reatinine level of 50% or more from baseline (1).
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.(
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edicine, Columbia, Missouri.The incidence of contrast-induced AKI depends in part
n the definition used and on a variety of patient-related
nd procedure-related factors (1–5,14). In a survey of
epresentative studies assessing the clinical and renal con-
equences of iodinated contrast media use from 1976 to
005, Finn (3) reported an incidence of CIN that ranged
rom 3.3% to 31.0%. McCullough (1) estimated that the
verall incidence of contrast-induced AKI has decreased
rom approximately 15% to 7% over the past decade,
ecause of greater awareness of risk markers for the devel-
pment of this syndrome, the development of less toxic
ontrast agents, and possibly the use of therapeutic inter-
entions to reduce risk. The incidence of contrast-induced
KI rises progressively with the number of risk markers and
s particularly high in patients with pre-existing chronic
idney disease and diabetes mellitus (1–5,14). In patients
ithout risk markers, the reported incidence of contrast-
nduced AKI has been 2% in most studies (1–6,14). The
ncidence remains low in patients with normal renal func-
ion (even if they have diabetes). The incidence increases to
% to 11% in patients with mild to moderate renal insuffi-
iency but rises to 40% or more in patients with volume
epletion or advanced heart failure (1–5). The reported
ncidence of contrast-induced AKI ranges from 9% to 30%
n patients with mild to moderate renal insufficiency and
iabetes mellitus and rises to 50% to 90% in those with
evere renal insufficiency and diabetic nephropathy (1–5).
Contrast-induced AKI has been associated with an in-
reased mortality risk, particularly in patients undergoing
ercutaneous coronary intervention (PCI) (1–13). Studies of
atients undergoing PCI, including those with acute myo-
ardial infarction, have reported in-hospital mortality rates
anging from 6.3% to 31.0% in patients with and from 0.6%
o 4.9% in those without contrast-induced AKI or CIN
1–11). In-hospital mortality rates in PCI patients requiring
ialysis range from 22.6% to 35.7% (1–5,8,9). Mortality
ates at 1 year range from 12.1% to 37.7% in patients with
nd from 3.7% to 14.4% in those without contrast-induced
KI or CIN (1–11).
Risk markers for contrast-induced AKI may be classified
s patient- or procedure-related (1–5,15–18). The most
mportant patient-related risk factor is pre-existing impair-
ent of renal function. Patients whose estimated glomeru-
ar filtration rates are 60 ml/min/1.73 m2 are thought to
ave impaired renal vasodilation and reduced clearance of
ontrast media, thus facilitating the hemodynamic changes
nd tubular toxicity associated with use of these agents
1–5,15–19). Diabetes mellitus has been cited as a risk
arker for contrast-induced AKI. This is clearly true when
iabetes mellitus is associated with chronic kidney disease,
articularly diabetic nephropathy (1–5,15–17). Opinion is
ivided as to whether diabetes mellitus alone serves as a
isk marker for contrast-mediated AKI (1–5). Older age
lso appears to be a risk factor for contrast-induced AKI
1–15,17). Advanced congestive heart failure and a moder-
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Glucose, Contrast, and Acute Kidney Injury April 6, 2010:1441–3te to severely reduced left ventricular ejection fraction have
een shown to be independent predictors of contrast-
nduced AKI, possibly related to impaired renal vasodilation
1–6,16). Hypovolemia and states characterized by low
ffective intravascular volume (cirrhosis, anemia) have also
een identified as risk markers of contrast-induced AKI due
n part to abnormal renal vasodilatory responses and de-
reased clearance of contrast media (1–5,15). Similarly,
ypotension regardless of cause also serves as a risk marker
1–5,15). Nephrotoxic drugs increase the sensitivity of the
idney to iodinated contrast media (1–5,15). These include
onsteroidal anti-inflammatory drugs, sulfonamide, and
minoglycoside agents alone or in combination with loop
iuretic agents (1–5,15). Cyclosporine A, mannitol, and
mphotericin B also contribute to contrast-induced renal
njury by various mechanisms (1–5,15). Metformin, al-
hough not nephrotoxic, facilitates contrast-induced AKI
1–5). Multiple myeloma is also considered a risk marker.
oth male and female sex, hypertension, acute myocardial
nfarction, multivessel coronary artery disease, peripheral
rtery disease, renal artery stenosis, hyperuricemia, and the
etabolic syndrome have been suggested as possible
atient-related risk markers on the basis of individual
tudies, but further research is required to confirm these
ndings (1–5,15,18).
Procedure-related risk markers for contrast-induced AKI
nclude the use of high-osmolar ionic contrast media,
ow-osmolar contrast media (compared with nonionic iso-
smolar contrast media), high volumes of contrast media,
nd multiple procedures requiring contrast media within
2 h (1–5,10,15–18). PCI or peripheral artery intervention,
oronary artery bypass surgery, and use of an intra-aortic
alloon pump (all of which predispose to atheroemboli)
epresent additional procedure-related risk markers for
ontrast-induced AKI (1–5,15). Mehran et al. (16) devel-
ped and validated a risk score for the prediction of CIN
fter PCI using many of the aforementioned risk markers.
The pathophysiology of contrast-induced AKI is not well
nderstood. Atheroemboli and hemodynamic alterations
eading to reduced renal perfusion may play a role in some
ases, as may other comorbidities that predispose patients
eceiving iodinated contrast to renal injury (1–5). Impaired
enal function at baseline (estimated glomerular filtration
ate 60 ml/min/1.73 m2) appears to be a prerequisite to
ontrast-induced AKI (1–5). Two major theories exist to
xplain this phenomenon: renal vasoconstriction and tubular
njury (1–5). Renal vasoconstriction is mediated by adeno-
ine, endothelin, the high osmolarity of some contrast
gents, and blockade of endogenous vasodilators such as
itric oxide and local prostaglandins (1–5). Renal blood flow
ecreases up to 30% 2 h after contrast exposure and up to
0% 4 h after exposure (1–5). This, in association with
olume depletion or reduced renal blood flow from heart
ailure, leads to increased viscosity, which predisposes to
edullary hypoxia and ischemia (1–5). This process may beacilitated by interstitial edema and may lead to loss of renal
aubular cells (1–5). Tubular injury is thought to result from
direct cytotoxic effect of iodinated contrast media, prob-
bly mediated by oxidative stress and the generation of
eactive oxygen species (1–5). Stasis of contrast media in
enal tubules may contribute to this phenomenon (1–5).
The study by Stolker et al. (19) in this issue of the
ournal demonstrates that pre-procedural blood glucose
evels are a risk marker for contrast-induced AKI in
atients without diabetes with acute myocardial infarc-
ion who undergo coronary angiography during their
ndex admissions. Such was not observed in patients with
iabetes, perhaps because of higher baseline risk for
ontrast-induced AKI in that population. These obser-
ations remained valid even after adjusting for confound-
ng variables, most importantly impaired renal function at
aseline. In a previous study, fasting blood glucose was
ound to be an independent predictor of contrast-induced
KI within the context of the metabolic syndrome (18).
he study by Stolker et al. (19) is the first to document
n increase in the risk for contrast-induced AKI with
rogressive elevations of blood glucose levels. Hypergly-
emia in patients without diabetes is commonly observed
n critically ill patients and occurs in more than 40% of
atients without diabetes with acute myocardial infarc-
ion (20). The etiology of hyperglycemia in this setting is
ncertain but may relate in part to stress-related neuro-
ormonal alterations, including stimulation of catechol-
mines, activation of the renin-angiotensin-aldosterone
ystem, and expression of various cytokines (20). In the
ritical care population, hyperglycemia in patients with-
ut diabetes is seen by some as a “stress test” denoting the
ailure of endogenous insulin reserves to adequately
ontrol blood glucose (20). Others have postulated that
yperglycemia occurs because of insulin resistance (20).
hether these mechanisms account for hyperglycemia in
atients with acute myocardial infarction is uncertain.
he results of this study are important not only because
hey identify a new risk marker for contrast-induced AKI
n patients without diabetes with acute myocardial in-
arction but because they raise the question of whether
nterventions such as intensive insulin therapy might
educe risk in this population. It is tempting, but prema-
ure, to extend the findings in this study to patients
ithout diabetes undergoing elective coronary angiogra-
hy and PCI. Further studies are necessary to determine
f pre-procedural hyperglycemia serves as a risk marker
or contrast-induced AKI in populations other than those
ith acute myocardial infarction who receive iodinated
ontrast media during coronary angiography.
eprint requests and correspondence: Dr. Martin A. Alpert,
niversity of Missouri Health Sciences Center, Room CE338,
Hospital Drive, Columbia, Missouri 65201. E-mail:
lpertm@health.missouri.edu.
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